SAN DIEGO, Aug. 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. announced today that Joachim P.H. Schupp, M.D. was appointed to the newly created position of vice president of medical affairs.
Dr. Schupp served most recently as vice president of clinical business solutions and clinical data services at ProSanos Corporation, a company specialized in the capture, integration and analysis of healthcare related data with focus on post-approval and pharmacovigilance studies. Dr. Schupp has more than 20 years experience in the global pharmaceutical industry. As global project leader at Novartis AG of Basel, Switzerland he was responsible for life cycle management of numerous projects and compounds in oncology, dermatology and wound healing, including several first-of-kind therapeutics. In this executive director position within project management, his team leadership is credited for the market approval of several drugs, including Femara(R) in the US and EU for breast cancer and Apligraf(R) in the US for venous and diabetic ulcers, and for the international development of Exjade(R), recently approved for transfusional hemosiderosis. Dr. Schupp received several prestigious awards at Ciba (later merged with Sandoz to form Novartis in 1996) and Novartis for his contributions. Dr. Schupp was a clinical research physician at Ciba where he directed international teams in the therapeutic area of inflammation. He received his M.D. from the Free University of Berlin and served for several years on the faculty at the University of Pretoria, South Africa prior to joining Ciba.
“We are delighted to have recruited Joachim to the team. His extensive pharmaceutical product development experience will be of great value as we execute late stage clinical development of CoFactor(R), and advance our product pipeline,” said James A. Merritt, ADVENTRX chief medical advisor.
About ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing treatments for cancer and infectious disease that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. More information can be found on the Company’s Web site at http://www.adventrx.com.
Forward Looking Statement
This press release contains forward-looking statements, within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on management’s current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled “Risk Factors” in ADVENTRX’s last annual report on Form 10-K and its Quarterly Reports on Form 10-Q, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions to forward-looking statements to reflect events or circumstances which occur after the date hereof.
ADVENTRX Pharmaceuticals, Inc.
CONTACT: Andrea Lynn, of ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866
Web site: http://www.adventrx.com/
Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/920134.html /
